Publications by authors named "S Mazzoni"

Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare.

View Article and Find Full Text PDF

Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens.

View Article and Find Full Text PDF

The integration and reuse of digital research products can be only ensured through the adoption of machine-actionable (meta)data standards enriched with semantic artefacts. This study compiles 540 semantic artefacts in environmental sciences to: i. examine their coverage in scientific domains and topics; ii.

View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates real-world dosing and symptom management practices for talquetamab, a new treatment for relapsed/refractory multiple myeloma, through interviews with healthcare providers (HCPs) and an expert panel discussion.
  • - Findings revealed diverse settings for step-up dosing (SUD), with a common practice of administering talquetamab biweekly and consideration for shifting to a monthly schedule for some patients showing positive responses to treatment.
  • - Recommendations for managing symptoms related to the treatment include using medications like dexamethasone and supportive products for oral and skin symptoms, highlighting the evolving strategies in real-world clinical settings while emphasizing the need for more data on optimal dosing.
View Article and Find Full Text PDF
Article Synopsis
  • Daratumumab treatment for light chain (AL) amyloidosis can lead to early refractoriness, leaving patients with fewer options if they relapse or respond poorly.
  • This study assessed the effectiveness of venetoclax therapy in AL patients with t(11;14) who had previously failed daratumumab, involving 31 subjects.
  • Results showed a 97% overall hematologic response to venetoclax, with strong organ responses in patients with cardiac (74%) and renal (46%) involvement, indicating promising potential for venetoclax as a salvage therapy after daratumumab failure.
View Article and Find Full Text PDF